Stage 2 final rule raises EHR meaningful use bar

Median OS was 35.0 months in the enzalutamide-alone arm vs 42.3 months in the combination arm.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

“NKT2152 demonstrated robust anti-tumor activity in a heavily pretreated, high-risk advanced clear cell renal cell carcinoma population," said Eric Jonasch, MD.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

"These final analysis results of LITESPARK-005 support belzutifan as a treatment option in refractory kidney cancer after checkpoint inhibitor and VEGFR-TKI therapy," says Brian Rini, MD.

Data from the TiNivo-2 trial showed a median progression-free survival of 5.7 months in the tivozanib plus nivolumab arm vs 7.4 months in tivozanib monotherapy arm.